The use of cyclosporine after cadaver kidney transplantation has improved graft survival at one and two years in most large controlled studies. Early acute and late chronic nephrotoxicity have emerged as the major drawbacks in the use of this new immunosuppressant. Because of the authors concerns about nephrotoxicity they began to use the drug selectively in their cadaver kidney transplant program early in 1984. They are reporting their experience with two cyclosporine protocols in 38 cadaver kidney transplants, one of which is a low-dose strategy they hope will allow optimal use of the drug.
|Original language||English (US)|
|Number of pages||3|
|Issue number||2 SUPPL. 1|
|State||Published - Dec 1 1986|
ASJC Scopus subject areas